Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study Meeting Abstract


Authors: Harrison, C.; Kremyanskaya, M.; Bose, P.; Gupta, V.; Rampal, R. K.; Lambert, J.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; Verstovsek, S.; Mesa, R.; Colak, G.; Klein, S.; Dutta, S.; Mascarenhas, J.
Abstract Title: Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study
Meeting Title: 64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 140
Issue: Suppl. 1
Meeting Dates: 2022 Dec 10-13
Meeting Location: New Orleans, LA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2022-11-15
Start Page: 9659
End Page: 9662
Language: English
ACCESSION: WOS:000893230302289
DOI: 10.1182/blood-2022-157735
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    338 Rampal